Ironwood Pharmaceuticals (IRWD) Debt to Equity (2013 - 2026)

Ironwood Pharmaceuticals has disclosed Debt to Equity across 13 years of filings, most recently posting -$2.69 for Q1 2026.

• Debt to Equity for Q1 2026 came in at -$2.69, down 133.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.69 (down 133.7% YoY), and the FY2025 annual result was -$2.23, down 74.78% from the prior year.
• Debt to Equity came in at -$2.69 for Q1 2026 at Ironwood Pharmaceuticals, down from -$2.23 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.23 in Q1 2022 to a low of -$164.82 in Q4 2023.
• The 5-year median for Debt to Equity is -$1.61 (2023), against an average of -$14.11.
• Across the five-year window, Debt to Equity jumped 99.22% in 2024 and slumped 133.7% in 2026, its largest moves.
• Ironwood Pharmaceuticals' Debt to Equity stood at $0.23 in 2022, then sank by 70873.49% to -$164.82 in 2023, then surged by 99.22% to -$1.28 in 2024, then tumbled by 74.78% to -$2.23 in 2025, then slipped by 20.62% to -$2.69 in 2026.
• The last three Debt to Equity figures came in at -$2.69 (Q1 2026), -$2.23 (Q4 2025), and -$2.21 (Q3 2025), per Business Quant data.